Do polyunsaturated fatty acids behave like an endogenous "polypill"?

Medical Hypotheses

Volumn 70, Issue 2, 2008, Pages 430-434

  Das, Undurti N ^a  

^a UND LIFE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ARACHIDIC ACID; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; EPOXY EICOSTRIENOIC ACID DERIVATIVE; FISH OIL; FOLIC ACID; GAMMA LINOLENIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CHILD HEALTH; CHOLESTEROL BLOOD LEVEL; CHOLINERGIC SYSTEM; COGNITION; DEPRESSION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FATTY ACID METABOLISM; HEMOSTASIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FATTY ACIDS, UNSATURATED; FOLIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; KIDNEY; MODELS, BIOLOGICAL; NERVOUS SYSTEM; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDYL-DIPEPTIDASE A;

EID: 37349082450     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.05.023     Document Type: Article

References (31)

1. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 360 (2002) 2-3
2. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419-1423
3. Hippisley-Cox J., and Coupland C. Effects of combinations of drugs on all mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 330 (2005) 1059-1063
4. Ridker P.M., Cook N., Lee I., Gordon D., Gaziano J.M., Manson J.E., et al. A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
5. Toole J., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
6. Das U.N. Essential fatty acids: biochemistry, physiology, and pathology. Biotechnol J 1 (2006) 420-439
7. Kumar K.V., and Das U.N. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med 214 (1997) 374-379
8. Okuda Y., Kawashima K., Sawada T., Tsurumaru K., Asano M., Suzuki S., et al. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun 232 (1997) 487-491
9. Kaergel E., Muller D.N., Honeck H., Theuer J., Shagdarsuren E., Mullally A., et al. P450-dependent arachidonic acid metabolism and angiotensin-II-induced renal damage. Hypertension 40 (2002) 273-279
10. Gilroy D.W. New insights into the anti-inflammatory actions of aspirin - induction of nitric oxide through the generation of epi-lipoxins. Mem Inst Oswaldo Cruz 100 1 (2005) 49-54
11. Wang W., and Diamond S.L. Does elevated nitric oxide production enhance the release of prostacyclin from shear stressed aortic endothelial cells?. Biochem Biophys Res Commun 233 (1997) 748-751
12. Das U.N. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essen Fatty Acids 65 (2001) 37-40
13. Levine L. Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells. Lipids Health Dis 2 (2003) 1
14. Birnbaum Y., Ye Y., Lin Y., Freeberg S.Y., Nishi S.P., Martinez J.D., et al. Augmentation of myocardial production of 15-epi-lipoxin A4 by pioglitazone and atorvastatin in the rat. Circulation 114 (2006) 929-935
15. Nordoy A., Bonaa K.H., Sandset P.M., Hansen J.B., and Nilsen H. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 20 (2000) 259-265
16. Das U.N. Long-chain polyunsaturated fatty acids in the growth and development of the brain and memory. Nutrition 19 (2003) 62-65
17. Kristensen S.D., Schmidt E.B., and Dyerberg J. Dietary supplementation with n - 3 polyunsaturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. J Intern Med 225 suppl (1989) 141-150
18. Dusing R., Struck A., Gobel B.O., Weisser B., and Vetter H. Effects of n - 3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 38 (1990) 315-319
19. Barcelli U.O., Weiss M., Beach D., Motz A., and Thompson B. High linoleic acid diets ameliorate diabetic nephropathy in rats. Am J Kidney Dis 16 (1990) 244-251
20. Singer P., Berger I., Moritz V., Forster D., and Taube C. N - 6 and N - 3 PUFA in liver lipids, thromboxane formation and blood pressure from SHR during diets supplemented with evening primrose, sunflowerseed or fish oil. Prostaglandins Leukot Essen Fatty Acids 39 (1990) 207-211
21. Grande J.P., Walker H.J., Holub B.J., Warner G.M., Keller D.M., Haugen J.D., et al. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 57 (2000) 1027-1040
22. Das U.N. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-β to prevent human essential hypertension. Eur J Clin Nutr 58 (2004) 195-203
23. Duffield J.S., Hong S., Vaidya V.S., Lu Y., Fredman G., Serhan C.N., et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 177 (2006) 5902-5911
24. Wiemer G., Fink E., Linz W., Hropot M., Scholkens B.E., and Wohlfart P. Furosemide enhances the release of endothelial kinins, nitric oxide and prostacyclin. J Pharmacol Exp Ther 271 (1994) 1611-1615
25. Harris R.C., Zhang M.Z., and Cheng H.F. Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol Scand 181 (2004) 543-547
26. Christensen J.H., Gustenhoff P., Korup E., Aaroe J., Toft E., Moller J.M., et al. n - 3 polyunsaturated fatty acids, heart rate variability and ventricular arrhythmias in post-AMI-patients. A clinical controlled trial. Ugeskr Laeger 159 (1997) 5525-5529
27. Christensen J.H., Christensen M.S., Dyerberg J., and Schmidt E.B. Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n - 3 fatty acids. Am J Clin Nutr 70 (1999) 331-337
28. Minami M., Kimura S., Endo T., Hamaue N., Hirafuji M., Togashi H., et al. Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 58 (1997) 1123-1129
29. Pita M.L., and Delgado M.J. Folic acid administration increases N - 3 polyunsaturated fatty acids in rat plasma and tissue lipids. Thromb Haemost 84 (2000) 420-423
30. Durand P., Prost M., and Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n - 3 polyunsaturated fatty acids. Atherosclerosis 121 (1996) 231-243
31. Das U.N. Folic acid says NO to vascular diseases. Nutrition 19 (2003) 686-692